EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Interrogating the Involvement of Autophagy, Senescence, and the Immune System in the Actions of Sacituzumab Govitecan as an Anticancer Agent

Melanie M Sinanian, Eesha Chakraborty, Ahmed M Elshazly, Shady Azzam, Nada Nassif, David A Gewirtz

Frontiers in Bioscience-Landmark · 2025

DOI: 10.31083/fbl39310 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Melanie M Sinanian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA. Hauptthemen laut MEDLINE: Camptothecin, Autophagy, Immunoconjugates, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are an emerging class of cancer therapeutics comprised of a tumor-targeting antibody linked to a cytotoxic payload. Sacituzumab govitecan (SG or IMMU-132) is comprised of a trophoblast cell-surface antigen 2 (TROP-2)-directed antibody linked to the topoisomerase 1 inhibitor, SN-38. SG was designed to exploit the overexpression of TROP-2, observed in a variety of different epithelial cancers, to enhance tumor-selective cytotoxicity while minimizing damage to normal tissues. SG is approved for pretreated metastatic triple-negative breast cancer (mTNBC) and hormone receptor-positive human epidermal growth factor receptor 2 (HER2) negative breast cancer patients. While SG has shown significant clinical benefit, the objective response rate (ORR) observed with SG in pretreated mTNBC patients in the Phase I/II basket study was 33.3%, indicating a heterogeneous response profile to SG. This article explores the potential influence of autophagy, senescence, and the patient’s immune system on the treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CamptothecinAutophagyImmunoconjugatesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCellular SenescenceImmune SystemTriple Negative Breast NeoplasmsNeoplasmsHumansFemaleAntigens, NeoplasmAnimals

Stichwörter der Autor:innen

TROP-2antibody-drug conjugatesautophagydrug combinationsimmune systemsacituzumab govitecansenescence

Substanzen

Camptothecinsacituzumab govitecanImmunoconjugatesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, 33516 Kafrelsheikh, Egypt.

Zitieren

APA

Sinanian, M. M., Chakraborty, E., Elshazly, A. M., Azzam, S., Nassif, N., & Gewirtz, D. A. (2025). Interrogating the Involvement of Autophagy, Senescence, and the Immune System in the Actions of Sacituzumab Govitecan as an Anticancer Agent. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl39310

Vancouver

Sinanian MM, Chakraborty E, Elshazly AM, Azzam S, Nassif N, Gewirtz DA. Interrogating the Involvement of Autophagy, Senescence, and the Immune System in the Actions of Sacituzumab Govitecan as an Anticancer Agent. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl39310

BibTeX
@article{Sinanian2025,
  author = {Sinanian, Melanie M and Chakraborty, Eesha and Elshazly, Ahmed M and Azzam, Shady and Nassif, Nada and Gewirtz, David A},
  title = {Interrogating the Involvement of Autophagy, Senescence, and the Immune System in the Actions of Sacituzumab Govitecan as an Anticancer Agent},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  doi = {10.31083/fbl39310}
}
Kostenlos starten →